Esperion Therapeutics, Inc. (NASDAQ:ESPR) had its target price upped by analysts at Needham & Company LLC from $58.00 to $72.00 in a report issued on Tuesday, The Fly reports. The firm currently has a “positive” rating on the biopharmaceutical company’s stock. Needham & Company LLC’s target price would suggest a potential upside of 59.40% from the company’s current price.

ESPR has been the topic of a number of other research reports. ValuEngine raised Esperion Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Zacks Investment Research cut Esperion Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, May 1st. Deutsche Bank AG started coverage on Esperion Therapeutics in a report on Friday, June 23rd. They set a “buy” rating and a $48.00 price objective on the stock. BidaskClub cut Esperion Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday. Finally, Citigroup Inc. reissued a “buy” rating on shares of Esperion Therapeutics in a report on Thursday, June 22nd. Eight research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $39.16.

Shares of Esperion Therapeutics (ESPR) traded up 26.6655% during midday trading on Tuesday, reaching $57.2148. The company’s stock had a trading volume of 2,909,768 shares. The stock’s market cap is $1.29 billion. Esperion Therapeutics has a one year low of $9.40 and a one year high of $57.38. The firm has a 50-day moving average of $44.47 and a 200-day moving average of $33.66.

COPYRIGHT VIOLATION NOTICE: “Esperion Therapeutics, Inc. (ESPR) Price Target Raised to $72.00” was reported by Daily Political and is owned by of Daily Political. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.dailypolitical.com/2017/08/08/esperion-therapeutics-inc-espr-price-target-raised-to-72-00.html.

Hedge funds have recently bought and sold shares of the company. Quantbot Technologies LP acquired a new stake in Esperion Therapeutics during the first quarter worth approximately $158,000. C WorldWide Group Holding A S acquired a new stake in Esperion Therapeutics during the first quarter worth approximately $162,000. Princeton Alpha Management LP acquired a new stake in Esperion Therapeutics during the first quarter worth approximately $205,000. Bank of Montreal Can raised its stake in Esperion Therapeutics by 1,006.7% in the first quarter. Bank of Montreal Can now owns 6,596 shares of the biopharmaceutical company’s stock worth $233,000 after buying an additional 6,000 shares during the last quarter. Finally, Aperio Group LLC acquired a new stake in Esperion Therapeutics during the second quarter worth approximately $249,000. 85.20% of the stock is owned by institutional investors and hedge funds.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

The Fly

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.